GSK Unveils New Investigational Oncology Treatments
The latest pipeline data offers potential new paths for patients facing resistant or hard-to-treat cancer types.
Updated on Oct. 16, 2026 in Cancer
Live Poll
Do you trust that large pharmaceutical companies are successfully prioritizing better outcomes for cancer patients?
GSK showcased its oncology pipeline at the 2026 ESMO conference, highlighting new developments in investigational therapies for various cancers. These treatments aim to address significant patient needs in conditions like gastrointestinal stromal tumors and other malignancies.
Why it matters
Developing targeted therapies is critical for patients facing treatment resistance or limited options in hard-to-treat cancers. By expanding its oncology portfolio, GSK focuses on creating new avenues for care where historical outcomes have been poor.
The disclosure covers clinical development for various cancer types, including investigational therapies for GIST and other solid tumors. Efficacy and safety outcomes for these assets remain under active investigation.
The players
GSK
A pharmaceutical company focused on researching and developing treatments for cancers with poor outcomes.
Hansoh Pharma
A pharmaceutical developer that granted GSK exclusive worldwide rights to specific oncology assets.
The details
Ris-Rez is an investigational antibody-drug conjugate targeting B7-H3, which utilizes a monoclonal antibody paired with a topoisomerase inhibitor to deliver treatment. Velzatinib is a small-molecule tyrosine kinase inhibitor designed to address KIT mutations common in gastrointestinal stromal tumors. Additionally, Mo-Rez is characterized by a drug-to-antibody ratio of 6.
Timeline
March 2014: Original Jemperli licensing agreement established.
October 16, 2026: GSK presents oncology pipeline data at the ESMO conference.
Health Landscape
The oncology field is currently moving toward highly specific, targeted therapies that address genetic mutations and protein expression patterns. This trend reflects a shift away from broader chemotherapies toward precision medicine for cancers like GIST.
These developments are in early or investigational stages, meaning they are not yet available for clinical use. Patients with specific cancer types like GIST should discuss their current treatment plan and participation in clinical trials with their oncologist.
The takeaway
The field of oncology continues to prioritize precision treatments for patients with high-resistance tumors. Patients should maintain regular communication with their oncology team to monitor for updates on trial availability or new therapeutic options.
Further reading
Learn more about the latest research and standard of care in the Cancer section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that large pharmaceutical companies are successfully prioritizing better outcomes for cancer patients?
